CIK 0001653087 · Accelerated filer<br>Smaller reporting company
Alector, Inc.
Sign in to watch- Ticker
- ALEC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 822933343
- Phone
- 415-231-5660
- Business address
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Alector LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $296,087
- in 3 filings
Net −$296,087. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 76 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-11 | LAVIGNE LOUIS J JR Director | Grant or award | +28,700 | 99,409 | ||
| 2025-06-11 | LAVIGNE LOUIS J JR Director | Grant or award · Stock Option (right to buy) | +9,450 | 9,450 | ||
| 2025-06-11 | DESOUZA ERROL B Director | Grant or award | +28,700 | 69,950 | ||
| 2025-06-11 | DESOUZA ERROL B Director | Grant or award · Stock Option (right to buy) | +9,450 | 9,450 | ||
| 2025-06-11 | Altmeyer Mark Director | Grant or award | +28,700 | 69,950 | ||
| 2025-06-11 | Altmeyer Mark Director | Grant or award · Stock Option (right to buy) | +9,450 | 9,450 | ||
| 2025-06-02 | GRASSO MARC Chief Financial Officer | Sale | −16,488 | $1.34 | $22K | 296,072 |
| 2025-06-02 | Kenkare-Mitra Sara President and Head of R&D | Sale | −23,890 | $1.34 | $32K | 512,252 |
| 2025-06-02 | Rosenthal Arnon Chief Executive Officer | Sale | −52,087 | $1.34 | $70K | 2,414,657 |
| 2025-05-02 | SCHELLER RICHARD H Director | Grant or award | +15,833 | 66,666 | ||
| 2025-03-03 | GRASSO MARC Chief Financial Officer | Sale | −18,091 | $1.47 | $27K | 312,560 |
| 2025-03-03 | Kenkare-Mitra Sara President and Head of R&D | Sale | −29,073 | $1.47 | $43K | 536,142 |
| 2025-03-03 | Rosenthal Arnon Chief Executive Officer | Sale | −40,330 | $1.47 | $59K | 2,466,744 |
| 2025-03-03 | Romano Gary Chief Medical Officer | Sale | −16,306 | $1.47 | $24K | 332,977 |
| 2024-12-02 | GRASSO MARC Chief Financial Officer | Sale | −16,489 | $2.52 | $42K | 330,651 |
| 2024-12-02 | Rosenthal Arnon Chief Executive Officer | Sale | −52,172 | $2.52 | $131K | 2,507,074 |
| 2024-12-02 | Kenkare-Mitra Sara President and Head of R&D | Sale | −26,500 | $2.52 | $67K | 565,215 |
| 2024-12-02 | Romano Gary Chief Medical Officer | Sale | −14,892 | $2.52 | $38K | 349,283 |
| 2024-10-01 | GRASSO MARC Chief Financial Officer | Grant or award | +216,400 | 347,140 | ||
| 2024-10-01 | Kenkare-Mitra Sara President and Head of R&D | Grant or award | +300,000 | 591,715 |
Page 6 of 23 · 454 trades